Abvc Biopharma (ABVC) Return on Capital Employed (2018 - 2025)
Abvc Biopharma (ABVC) has disclosed Return on Capital Employed for 10 consecutive years, with 0.48% as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 379.0% year-over-year to 0.48%, compared with a TTM value of 0.48% through Dec 2025, up 379.0%, and an annual FY2025 reading of 0.88%, up 743.0% over the prior year.
- Return on Capital Employed was 0.48% for Q4 2025 at Abvc Biopharma, down from 0.46% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 0.44% in Q2 2025 and bottomed at 6.61% in Q1 2024.
- Average Return on Capital Employed over 5 years is 2.06%, with a median of 1.78% recorded in 2021.
- The sharpest move saw Return on Capital Employed surged 958bps in 2021, then plummeted -449bps in 2024.
- Year by year, Return on Capital Employed stood at 1.25% in 2021, then plummeted by -169bps to 3.37% in 2022, then soared by 64bps to 1.22% in 2023, then tumbled by -250bps to 4.27% in 2024, then surged by 89bps to 0.48% in 2025.
- Business Quant data shows Return on Capital Employed for ABVC at 0.48% in Q4 2025, 0.46% in Q3 2025, and 0.44% in Q2 2025.